接受 CAR-T 细胞治疗的成人 Burkitt 淋巴瘤患者结局

Burkitt lymphoma (BL) is an aggressive B-cell lymphoma that is associated with poor outcomes in patients with relapsed/refractory disease. This multicenter, retrospective study evaluated real-world CD19 chimeric antigen receptor (CAR) T-cell therapy outcomes in patients with relapsed/refractory BL using data abstracted from the medical records. In total, 31 patients received CAR T cells after a median of 3 previous therapies (range, 1-6). Patients received axicabtagene ciloleucel (n = 19), lisocabtagene maraleucel (n = 4), tisagenlecleucel (n = 4), or other agents (n = 4). Grade 1 to 2 cytokine release syndrome occurred in 83.

9% of patients (grade 3, 65%), and grade 1 to 2 immune effector cell-associated neurotoxicity syndrome (ICANS) occurred in 29% of patients (grade 3, 19. 4%). The 28-day mortality rate was 16. 1%, including 1 patient who died from grade 5 ICANS. The overall response rate at 1 month was 58. 0% with a complete response (CR) rate of 41.

9%; however, the 6-month CR rate was only 19. 4%. The median progression-free survival was 2. 3 months (95% confidence interval, 1. 0-9. 0), and the median overall survival was 6. 0 months (95% confidence interval, 1. 9-11. 5). Three patients (9. 7%) received consolidative allogeneic stem cell transplants, but all subsequently relapsed.

In conclusion, CD19 CAR T-cell therapy infrequently delivers long-term disease control in BL.

Further investigation is needed to determine the most effective alternative management strategy for these patients.